AstraZeneca and Merck Report OlympiA Phase 3 Trial Finds Lynparza Significantly Enhances Survival in Early Stage Breast Cancer
AstraZeneca in collaboration with Merck—recognized as MSD outside the US and Canada—has unveiled enduring data from the OlympiA phase 3 trial, demonstrating that Lynparza (olaparib) achieves long-lasting, meaningful clinical improvements in overall survival (OS), invasive disease-free survival (IDFS), and distant […]